Granules India Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Granules India today announced that its wholly-owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), located in Chantilly, Virginia, US, has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA), with a Voluntary Action Indicated (VAI) classification. The inspection was conducted from 30 March to 03 April 2026, during which four Form 483 observations were issued.

The USFDA conducted an inspection of the facility from 30 March to 3 April 2026 and issued four Form 483 observations. The receipt of the EIR with a VAI classification indicates the successful closure of the inspection.

The company said the facility remains an important part of its global manufacturing and supply network, with continued focus on quality systems, regulatory compliance, and patient safety.

Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The company?s consolidated net profit climbed 32.58% to Rs 201.56 crore on 22.81% increase in revenue from operations to Rs 1,470.60 crore in Q4 FY26 over Q4 FY25.

Powered by Capital Market - Live News

Granules India announced that the Board of Directors of the Company at its meeting held on 29 April 2026, inter alia, have recommended the final dividend of Rs 1.75 per equity Share (i.e. 175%) , subject to the approval of the shareholders.

Granules India announced that the 35th Annual General Meeting(AGM) of the company will be held on 6 August 2026.